Navigation Links
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. CoFactor plus 5-FU (5-Fluorouracil) was determined to be a safe, well-tolerated and active treatment regimen in advanced breast cancer patients who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23% objective response rate with CoFactor plus 5-FU based on investigators' assessments. Objective response rate was based on the number of complete responses and partial responses observed in this study.

The poster presentation, entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," was presented by Dr. Joachim P.H. Schupp, Vice President of Medical Affairs on June 2, 2008.

Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced breast cancer, has demonstrated response rates between 14% and 26% when studied as monotherapy in patients with advanced breast cancer who failed prior treatment with anthracyclines and taxanes. In this well-defined study population, two recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepil
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
(Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... REDWOOD CITY, Calif. , June 28 Codexis, ... has joined the company as Senior Vice President, Commercial Operations, ... product management and manufacturing operations worldwide.  He will report to ... and Enzyme Products.   , ...
... , June 28 Graymark Healthcare Inc. (Nasdaq: GRMH ... innovator in comprehensive care for obstructive sleep apnea today announced that it ... over 750 patients. In addition they served over 1275 patients through their ... , Graymark ...
Cached Medicine Technology:Codexis Names Peter Strumph SVP, Commercial Operations 2Graymark Healthcare Sells Record Number of CPAP Devices in Q2 2010 2Graymark Healthcare Sells Record Number of CPAP Devices in Q2 2010 3
(Date:12/26/2014)... “Many people become overwhelmed by the thought of ... phone calls with insurance companies,” The Jones Firm explains ... free eBook on pedestrian and bicycle accidents . ... auto accident claims assures the injured individual that a ... their case while they focus on recovering. , ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... ... based on clinical performance according to Thomson Reuters, a leading provider of information and solutions ... ... Care has been named one of the nation,s top 10 health systems based on ...
... its natural antioxidants protect the skin , FRIDAY, Aug. 14 ... the risk of treatment-linked skin toxicity by two-thirds in ... , Skin reactions are a common side effect of cancer ... they can be expensive and often have their own side ...
... , , WASHINGTON, Aug. 14 ... injunction against the enforcement of an Ohio law strictly regulating the ... Dr. Charmaine Yoest, CEO and President of Americans United for ... Parenthood and other abortion providers have readily admitted that they administer ...
... were at risk for psychosocial problems , FRIDAY, Aug. ... deployed U.S. Army soldiers are at high risk for ... experienced by the parent who is still at home, ... spouses (mainly wives) of 101 deployed Army personnel. Participants ...
... , , MINNEAPOLIS, Aug. 14 ... is pleased to announce the recipients for the 2009 Jay ... by Courage Center to people with disabilities who have achieved ... Award which acknowledges and honors a behind-the-scenes caregiver vital to ...
... FARMINGTON HILLS, Mich., Aug. 14 Work and economy related stress ... a new independent survey conducted by American Laser Centers, the largest ... of the respondents who took part in the survey (47 percent) ... stress. , , The physical toll ...
Cached Medicine News:Health News:Advocate Named One Of The Nation's Top 10 Health Systems 2Health News:Advocate Named One Of The Nation's Top 10 Health Systems 3Health News:Wine May Shield Breast Cancer Patients From Radiation Side Effects 2Health News:Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486 2Health News:Kids of Deployed Soldiers Vulnerable to Stress 2Health News:Courage Center Names 2009 Phillips Award Recipients 2Health News:Courage Center Names 2009 Phillips Award Recipients 3Health News:Courage Center Names 2009 Phillips Award Recipients 4
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: